Please ensure Javascript is enabled for purposes of website accessibility

Why PDL BioPharma Stock Is Soaring Today

By Keith Speights - Oct 23, 2019 at 11:39AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A letter from an activist investor to the company's board of directors is lighting a fire beneath this healthcare stock.

What happened

Shares of PDL BioPharma (PDLI) had soared 15.1% higher as of 11:26 a.m. EDT on Wednesday. The big jump came after a large shareholder, Engine Capital, called for PDL's board of directors "to immediately cease its investment activities and commence a review of strategic alternatives, including a possible sale or liquidation of the Company."

So what

Engine Capital owns around 5.3% of PDL BioPharma. When a shareholder with such a significant stake pushes a company's board to do something, it will at least get the board's attention.

Red "for sale" sign with white letters and a red arrow pointing left

Image source: Getty Images.

In this case, Engine Capital thinks that PDL is "just grasping at straws" with its strategy to build a portfolio of investments. It believes that PDL BioPharma stock is undervalued and that the best way to unlock value for shareholders is to either sell or liquidate the company.

The letter that Engine Capital's Arnaud Ajdler and Brad Favreau sent to PDL's board of directors was very direct. It stated that the directors were being put "on notice" and will be "closely watched," adding that "any attempt to utilize the company's cash for further acquisitions or investments will be vehemently opposed."

Shareholders probably would win if PDL BioPharma is acquired by another company or liquidates its assets. The stock currently trades at roughly half of its book value.

Now what

PDL BioPharma is certainly a unique example of a healthcare stock. It doesn't develop drugs or medical devices itself, but instead invests in other companies that do. If Engine Capital has its way, those investments will come to an immediate halt. 

What will PDL BioPharma's board of directors do in response to Engine Capital's demands? That remains to be seen. The company hasn't publicly responded to Engine Capital's letter yet. Stay tuned.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PDL BioPharma, Inc. Stock Quote
PDL BioPharma, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.